Women's Angiographic Vitamin and Estrogen trial: Design and methods

Judith Hsia; Edwin L. Alderman; Joel I. Verter; William J. Rogers; Paul Thompson; Barbara V. Howard; Frederick R. Cobb; Pamela Ouyang; Jean Claude Tardif; Lyall Higginson; Vera Bittner; Ivan Barofsky; Michael Steffes; David J. Gordon; Michael Proschan; Naji Younes; David Waters

doi:10.1016/S0197-2456(02)00237-4

Women's Angiographic Vitamin and Estrogen trial: Design and methods

Judith Hsia, Edwin L. Alderman, Joel I. Verter, William J. Rogers, Paul Thompson, Barbara V. Howard, Frederick R. Cobb, Pamela Ouyang, Jean Claude Tardif, Lyall Higginson, Vera Bittner, Ivan Barofsky, Michael Steffes, David J. Gordon, Michael Proschan, Naji Younes, David Waters

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

The Women's Angiographic Vitamin and Estrogen trial was a randomized, double-blind, placebo-controlled study designed to test the efficacy of estrogen replacement and antioxidant vitamins for preventing angiographic progression of coronary artery disease. Postmenopausal women with one or more angiographically documented coronary stenoses of 15-75% at baseline were assigned in a 2×2 factorial randomization to active hormone replacement therapy (conjugated estrogens for women who had had a hysterectomy or conjugated estrogens with medroxyprogesterone for women with intact uteri) or placebo and to active vitamins E and C or their placebos. Seven clinical centers, five in the United States and two in Canada, randomized 423 women between July 1997 and July 1999. Quantitative coronary angiography was performed at baseline and repeated after projected mean follow-up of 3 years.

Original language	English (US)
Pages (from-to)	708-727
Number of pages	20
Journal	Controlled clinical trials
Volume	23
Issue number	6
DOIs	https://doi.org/10.1016/S0197-2456(02)00237-4
State	Published - Dec 2002
Externally published	Yes

Keywords

Antioxidants
Coronary angiography
Coronary heart disease
Estrogen

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/S0197-2456(02)00237-4

Cite this

Hsia, J., Alderman, E. L., Verter, J. I., Rogers, W. J., Thompson, P., Howard, B. V., Cobb, F. R., Ouyang, P., Tardif, J. C., Higginson, L., Bittner, V., Barofsky, I., Steffes, M., Gordon, D. J., Proschan, M., Younes, N., & Waters, D. (2002). Women's Angiographic Vitamin and Estrogen trial: Design and methods. Controlled clinical trials, 23(6), 708-727. https://doi.org/10.1016/S0197-2456(02)00237-4

Hsia, J, Alderman, EL, Verter, JI, Rogers, WJ, Thompson, P, Howard, BV, Cobb, FR, Ouyang, P, Tardif, JC, Higginson, L, Bittner, V, Barofsky, I, Steffes, M, Gordon, DJ, Proschan, M, Younes, N & Waters, D 2002, 'Women's Angiographic Vitamin and Estrogen trial: Design and methods', Controlled clinical trials, vol. 23, no. 6, pp. 708-727. https://doi.org/10.1016/S0197-2456(02)00237-4

@article{59e68921dfa04056af41d4e4fda457e5,

title = "Women's Angiographic Vitamin and Estrogen trial: Design and methods",

abstract = "The Women's Angiographic Vitamin and Estrogen trial was a randomized, double-blind, placebo-controlled study designed to test the efficacy of estrogen replacement and antioxidant vitamins for preventing angiographic progression of coronary artery disease. Postmenopausal women with one or more angiographically documented coronary stenoses of 15-75% at baseline were assigned in a 2×2 factorial randomization to active hormone replacement therapy (conjugated estrogens for women who had had a hysterectomy or conjugated estrogens with medroxyprogesterone for women with intact uteri) or placebo and to active vitamins E and C or their placebos. Seven clinical centers, five in the United States and two in Canada, randomized 423 women between July 1997 and July 1999. Quantitative coronary angiography was performed at baseline and repeated after projected mean follow-up of 3 years.",

keywords = "Antioxidants, Coronary angiography, Coronary heart disease, Estrogen",

author = "Judith Hsia and Alderman, {Edwin L.} and Verter, {Joel I.} and Rogers, {William J.} and Paul Thompson and Howard, {Barbara V.} and Cobb, {Frederick R.} and Pamela Ouyang and Tardif, {Jean Claude} and Lyall Higginson and Vera Bittner and Ivan Barofsky and Michael Steffes and Gordon, {David J.} and Michael Proschan and Naji Younes and David Waters",

note = "Funding Information: This work was supported by NIH contracts NO1-HV-68165, NO1-HV-68166, NO1-HV-68167, NO1-HV-68168, NO1-HV-68169, NO1-HV-68170. ",

year = "2002",

month = dec,

doi = "10.1016/S0197-2456(02)00237-4",

language = "English (US)",

volume = "23",

pages = "708--727",

journal = "Controlled clinical trials",

issn = "0197-2456",

publisher = "Elsevier BV",

number = "6",

}

TY - JOUR

T1 - Women's Angiographic Vitamin and Estrogen trial

T2 - Design and methods

AU - Hsia, Judith

AU - Alderman, Edwin L.

AU - Verter, Joel I.

AU - Rogers, William J.

AU - Thompson, Paul

AU - Howard, Barbara V.

AU - Cobb, Frederick R.

AU - Ouyang, Pamela

AU - Tardif, Jean Claude

AU - Higginson, Lyall

AU - Bittner, Vera

AU - Barofsky, Ivan

AU - Steffes, Michael

AU - Gordon, David J.

AU - Proschan, Michael

AU - Younes, Naji

AU - Waters, David

N1 - Funding Information: This work was supported by NIH contracts NO1-HV-68165, NO1-HV-68166, NO1-HV-68167, NO1-HV-68168, NO1-HV-68169, NO1-HV-68170.

PY - 2002/12

Y1 - 2002/12

N2 - The Women's Angiographic Vitamin and Estrogen trial was a randomized, double-blind, placebo-controlled study designed to test the efficacy of estrogen replacement and antioxidant vitamins for preventing angiographic progression of coronary artery disease. Postmenopausal women with one or more angiographically documented coronary stenoses of 15-75% at baseline were assigned in a 2×2 factorial randomization to active hormone replacement therapy (conjugated estrogens for women who had had a hysterectomy or conjugated estrogens with medroxyprogesterone for women with intact uteri) or placebo and to active vitamins E and C or their placebos. Seven clinical centers, five in the United States and two in Canada, randomized 423 women between July 1997 and July 1999. Quantitative coronary angiography was performed at baseline and repeated after projected mean follow-up of 3 years.

AB - The Women's Angiographic Vitamin and Estrogen trial was a randomized, double-blind, placebo-controlled study designed to test the efficacy of estrogen replacement and antioxidant vitamins for preventing angiographic progression of coronary artery disease. Postmenopausal women with one or more angiographically documented coronary stenoses of 15-75% at baseline were assigned in a 2×2 factorial randomization to active hormone replacement therapy (conjugated estrogens for women who had had a hysterectomy or conjugated estrogens with medroxyprogesterone for women with intact uteri) or placebo and to active vitamins E and C or their placebos. Seven clinical centers, five in the United States and two in Canada, randomized 423 women between July 1997 and July 1999. Quantitative coronary angiography was performed at baseline and repeated after projected mean follow-up of 3 years.

KW - Antioxidants

KW - Coronary angiography

KW - Coronary heart disease

KW - Estrogen

UR - http://www.scopus.com/inward/record.url?scp=0036916805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036916805&partnerID=8YFLogxK

U2 - 10.1016/S0197-2456(02)00237-4

DO - 10.1016/S0197-2456(02)00237-4

M3 - Article

C2 - 12505248

AN - SCOPUS:0036916805

SN - 0197-2456

VL - 23

SP - 708

EP - 727

JO - Controlled clinical trials

JF - Controlled clinical trials

IS - 6

ER -

Women's Angiographic Vitamin and Estrogen trial: Design and methods

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this